Maraviroc

(asked on 25th September 2019) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent assessment he has had made of the effectiveness of Maraviroc in patients with progressive multifocal leukoencephalopathy (PML).


Answered by
Nadine Dorries Portrait
Nadine Dorries
This question was answered on 30th September 2019

Maraviroc (brand name Celsentri) is currently authorised through the European centralised procedure for the treatment of patients who are infected with HIV type 1. It is used in combination other HIV medicines.

The Medicines and Healthcare products Regulatory Agency which is responsible for the regulation of medicines in the United Kingdom is not aware of any application for maraviroc for use in patients with progressive multifocal leukoencephalopathy (PML) and cannot therefore comment on the efficacy of this drug in patients with PML.

Reticulating Splines